Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical tr…
Biotechnology
US, Gaithersburg [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 39.63 | -231.33 | 165.68 | |
| Graham Fair Price | -39.63 | 5.38 | 8.90 | |
| PEG | 260.47 | 0.90 | -0.25 | |
| Price/Book | 19.04 | 7.12 | 5.98 | |
| Price/Cash Flow | 68.22 | -92.17 | 54.79 | |
| Prices/Earnings | 235.75 | -122.73 | 36.55 | |
| Price/Sales | 95.91 | 90.02 | 45.95 | |
| Price/FCF | 68.22 | -92.17 | 54.79 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -0.97 | 0.98 | 0.99 | |
| Operating Margin | 69.56 | -0.40 | 0.24 | |
| ROA | -61.61 | < 0.005 | 0.02 | |
| ROE | 0.04 | -0.01 | -64.54 | |
| ROIC | 0.02 | -0.03 | 8.54 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.11 | -0.10 | -3.02 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 1.33 | -2.05 | 53.94 | |
| EPS QOQ | 1.47 | -1.37 | -6.86 | |
| FCF QOQ | 3.94 | -1.72 | -56.21 | |
| Revenue QOQ | 3.22 | -0.38 | -88.26 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 7.11 | 100.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.17 | 0.15 | -10.66 | |
| Quick Ratio | 5.94 | 5.35 | -9.90 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 9.28 | 9.41 | 1.38 | |
| Cash | 13.43 | 10.88 | -18.96 | |
| Capex | -0.10 | -0.12 | -20.42 | |
| Free Cash Flow | 1.01 | -0.73 | -28.26 | |
| Revenue | 1.21 | 0.74 | -38.40 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad